Table 5.
Summary of transfusion independence (ITT analysis set)
| Baseline | 3-day treatment group (n = 34) | 5-day treatment group (n = 98) | Total (N = 132) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Dependent | Independent | NA | Total | Dependent | Independent | NA | Total | Dependent | Independent | NA | |
| Dependent | 27 (79.4) | 14 (51.9) | 13 (48.1) | 0 | 61 (62.2) | 36 (59.0) | 25 (41.0) | 0 | 88 (66.7) | 50 (56.8) | 38 (43.2) | 0 |
| Independent | 7 (20.6) | 2 (28.6) | 5 (71.4) | 0 | 37 (37.8) | 14 (37.8) | 22 (59.5) | 1 (2.7) | 44 (33.3) | 16 (36.4) | 27 (61.4) | 1 (2.3) |
Percentages in ‘Total’ column were calculated with the number of ITT patients treated as denominator; percentages of subgroup were calculated with the number of patients per baseline subgroup as denominator
ITT analysis set included all patients who received at least 1 dose of decitabine
ITT intent to treat, NA not applicable (patients who were treated less than 8 weeks and had no blood transfusion records were reported)